CIRM: Phase III clinical trial targeting Lou Gehrig’s disease gets US$15.9 million investment
Musculoskeletal disorders are injuries or pain in the human musculoskeletal system, including the joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a particularly nasty, almost always fatal neurological condition that has no effective treatment and no cure. Now the California Institute for Regenerative Medicine (CIRM) is investing $15.9 million in a therapy to try and change that. ALS attacks motor neurons, the cells in the brain and spinal cord that control our muscles and movement. Over time the disease destroys a person’s ability to speak, to swallow, to move, even to breathe. BrainStorm Cell Therapeutics has developed a therapy they hope will slow down, and potentially even stop, the progression...
